Business
MustGrow: CEO Letter to Shareholders 2025
Saskatoon, Saskatchewan--(Newsfile Corp. - December 18, 2025) - MustGrow Biologics Corp. (TSXV: ...
About this update from Mustgrow Biologics Corp.
[{"type":"text","content":"MustGrow: CEO Letter to Shareholders 2025Saskatoon, Saskatchewan--(Newsfile Corp. - December 18, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the \"Company\" or \"MustGrow\") is pleased to issue a letter to shareholders from Corey Giasson, MustGrow's President and CEO. Dear MustGrow shareholders and stakeholders,I hope everyone is well and ready to enjoy a peaceful and festive holiday season with family and friends. I am writing this letter to share our excitement in what was a truly transformational year for MustGrow as we transitioned from product development to commercialization, with our own mustard-derived TerraSanteTM biofertility product sales expansion in the U.S. and through our sales and distribution division, NexusBioAg, in Canada. For TerraSanteTM, the response from large U.S. commercial farming operations has exceeded our expectations as exhibited through strong repeat demand. For our Canadian distribution business, NexusBioAg, we are anticipating a typical cyclical rebound for farmers and our business in 2026. TerraSanteTMQuite simply: We experienced strong demand, farmer feedback has confirmed the economics and return-on-investment proposition and market size is significant and validated, and we have already begun executing our 2026 plan to increase manufacturing scale to meet this demand. For the first half of 2025, TerraSanteTM biofertility sales were modest, as farmers and retailers in the U.S. purchased product for field trials on only a small portion of acres. In the second half of 2025 we witnessed an increase in repeat demand, as initial field trials proved successful. We could not fully supply this late-season demand due to intentionally conservative inventory planning earlier in the year — a clear sign that TerraSante™'s market acceptance is accelerating. Like some of the commercial farmers that used TerraSanteTM, we were impressed with the product performance in terms of yield, crop health, and economics. In September, we moved quickly to produce additional inventories to meet the growing demand for Q4-2025 and Q1-2026 deliveries. This experience has underlined our thesis that once the major retailers and fruit & vegetable commercial farmers use our biofertility product, they are likely to want more! Even though our marketing has been minimal, the performance...